Technology Takeda to Acquire Nimbus Therapeutics’ Highly Selective, Allosteric TYK2 Inhibitor to Address… AIT News Desk Dec 14, 2022 - Nimbus to receive $4 billion in upfront cash, and up to $2 billion in commercial milestone payments - - NDI-034858 has potential best-in-class…
Technology Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858… AIT News Desk Dec 14, 2022 Takeda announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2)…